Home CONTACT Neoplasma 2017 Neoplasma Vol.64, No.1, p.74-80,2017

Journal info

6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.64, No.1, p.74-80,2017

Title: EGCG sensitizes human nasopharyngeal carcinoma cells to TRAIL-mediated apoptosis by activation NF-κB
Author: P. LI, S. LI, D. YIN, J. LI, L. WANG, C. HUANG, X. YANG

Abstract: Aim of presented study was to investigate whether EGCG could sensitize TRAIL resistant NPC cells to TRAIL-mediated apoptosis. Three human NPC cell-lines CNE-1, CNE-2, C666-1 and a non-transformed nasopharyngeal epithelium cell-line NP-69 were treated with EGCG or/and TRAIL. The apoptosis and TRAIL receptors were determined by flow cytometric analysis. The protein expression was determined by western blotting. Mitochondrial transmembrane potential was dertemined by DiOC6 (3). C666-1 cell-line was the only one that resistant to TRAIL and selected to be treated with EGCG. ECGC could sensitize C666-1 to TRAIL. Combinatorial treatments led to decrease expression of Bcl-XL, Bcl-2, FADD and FLIP and enhance activation of capase-3, -8, -9. The DiOC6 (3) negative cell rate was increased and p65 of NF-κB, XIAP and survivin expression was reduced by the combination treatment.
In summary, EGCG sensitizes NPC cells to TRAIL-mediated apoptosis via modulation of extrinsic and intrinsic apoptotic pathways and inhibition of NF-κB activation.

Keywords: nasopharyngeal carcinoma, TRAIL, EGCG, apoptosis, NF-κB
Published online: 10-Jan-2017
Year: 2017, Volume: 64, Issue: 1 Page From: 74, Page To: 80

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.